Diligence memo · auto-generated · as of July 2, 2026
Lb Pharmaceuticals Inc
Lb Pharmaceuticals Inc looks fair against its niche peers and is at-risk on financing cadence.
Businessfiled
Lb Pharmaceuticals Inc operates in Pharmaceuticals, based in NEW YORK.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Lb Pharmaceuticals Inc has raised $141M in disclosed capital across 9 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $111M on 2023-08-29.
Most recent recorded round closed around 2023-08-29.
Valuation (modeled)modeled
Provath models Lb Pharmaceuticals Inc at approximately $1.5B (range $527M–$2.3B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.80× the median modeled value of Series D+ Pharmaceuticals companies in 2022–2024 (18 peers) — value vs value, same stage and era. Within the normal band (80% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 8 months.
Last raise 2.8 yr ago; this sector typically re-raises about every 13 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round was 1.6× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 95% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 92% of those peers.
Closest niche peers: Paragon Biosciences Emalex Capital, Inc., TrialSpark, Inc., Fog Pharmaceuticals, Inc., MAPS Public Benefit Corp, Karyopharm Therapeutics Inc..
Peoplefiled
15 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.